



Ingmar A F M Heijnen

Contact

Ingmar A F M Heijnen

Publications (3)

Oechtering J, Lincke T, Schaedelin S, Décard B, Maceski A, Orleth A, Meier S, Willemse E, Buchmann A, Khalil M, Derfuss T, Benkert P, Heijnen I, Regeniter A, Müller S, Achtnichts L, Lalive P, Salmen A, Pot C, Gobbi C, Kappos L, Granziera C, Leppert D, Schlaeger R, Lieb J, Kuhle J, Swiss MS Cohort Study. Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. *Ann Neurol* 2022; 91:814–820.

Urwyler P, Sendi P, Albrich W, Stüssi-Helbling M, Huber L, Bacci M, Camacho-Ortiz A, Sumer J, Thoma R, Trendelenburg M, Heijnen I, Moser S, Charitos P, Osthoff M. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). *Trials* 2021; 22:1.

Taverna C, Zucca E, Heijnen I, Rusterholz C, Rondeau S, Biaggi Rudolf C, Lohri A, Vorobiof D, Rauch D, Raats J, Laszlo D, Vanazzi A, Del Giglio A, Cevreska L, Pabst T, Mingrone W, Hitz F, Martinelli G, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. *J Clin Oncol* 2015; 34:495–500.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch